Top Line: Thrombocytopenia is one of the most common dose-limiting toxicities seen with cytotoxic chemotherapy.
The Study: The phase 3 RECITE trial enrolled 165 patients with GI (mostly colorectal)cancers and persistent chemo-induced thrombocytopenia during oxaliplatin-based chemo and randomized them 2:1 to weekly romiplostim versus placebo. Romi-what? Romiplastin is a thrombopoietin-receptor agonist analogous to the G-CSF receptor agonist pegfilgrastim routinely used to increase neutrophil count. Eligible patients had platelet counts ≤85×10⁹/L despite adequate recovery time from the prior cycle. The primary endpoint—no chemo dose modifications due to thrombocytopenia in cycles 2–3—was achieved in 84% with romiplostim versus 36% with placebo (OR 10.16, P<0.001). Platelet recovery was faster (median 1.1 vs 2.1 weeks) and nadir platelet counts were higher (87 vs 58×10⁹/L). Post-hoc analyses suggested improved chemo adherence: 95% versus 73% completed all three planned cycles. You may ask why it has taken until 2026 to develop such a blockbuster chemo-adjunct. The reason is two-fold: (1) commonsense fears of aggravating pre-existing malignancy-related hypercoagulability and (2) terrifying reports with earlier versions of paradoxically inducing profound transfusion-dependent thrombocytopenia due to recipients developing neutralizing antibodies against endogenous thrombopoietin–thus romiplastin being engineered specifically not to resemble native thrombopoietin, avoiding cross-reactive antibodies. With this in mind, 2% of patients experienced thromboembolic events in the romiplostim arm versus none in the placebo arm. The toughest question yet to be answered will be cost-effectiveness, specifically when the endpoint here is chemo adherence rather than cancer survival or catastrophic bleeding events.
TBL: Romiplostim substantially reduces thrombocytopenia-driven chemo reductions and delays in patients receiving oxaliplatin-based regimens. | Al-Samkari, N Engl J Med 2026
The Study: The phase 3 RECITE trial enrolled 165 patients with GI (mostly colorectal)cancers and persistent chemo-induced thrombocytopenia during oxaliplatin-based chemo and randomized them 2:1 to weekly romiplostim versus placebo. Romi-what? Romiplastin is a thrombopoietin-receptor agonist analogous to the G-CSF receptor agonist pegfilgrastim routinely used to increase neutrophil count. Eligible patients had platelet counts ≤85×10⁹/L despite adequate recovery time from the prior cycle. The primary endpoint—no chemo dose modifications due to thrombocytopenia in cycles 2–3—was achieved in 84% with romiplostim versus 36% with placebo (OR 10.16, P<0.001). Platelet recovery was faster (median 1.1 vs 2.1 weeks) and nadir platelet counts were higher (87 vs 58×10⁹/L). Post-hoc analyses suggested improved chemo adherence: 95% versus 73% completed all three planned cycles. You may ask why it has taken until 2026 to develop such a blockbuster chemo-adjunct. The reason is two-fold: (1) commonsense fears of aggravating pre-existing malignancy-related hypercoagulability and (2) terrifying reports with earlier versions of paradoxically inducing profound transfusion-dependent thrombocytopenia due to recipients developing neutralizing antibodies against endogenous thrombopoietin–thus romiplastin being engineered specifically not to resemble native thrombopoietin, avoiding cross-reactive antibodies. With this in mind, 2% of patients experienced thromboembolic events in the romiplostim arm versus none in the placebo arm. The toughest question yet to be answered will be cost-effectiveness, specifically when the endpoint here is chemo adherence rather than cancer survival or catastrophic bleeding events.
TBL: Romiplostim substantially reduces thrombocytopenia-driven chemo reductions and delays in patients receiving oxaliplatin-based regimens. | Al-Samkari, N Engl J Med 2026